Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 15, 2025, the company has repurchased a total of 2,768,487 ordinary fully paid securities, including 136,041 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services. The company focuses on delivering medical testing services across Australia, catering to both private and public healthcare sectors.
Average Trading Volume: 785,388
Technical Sentiment Signal: Buy
Current Market Cap: A$546.7M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.